Monday, September 28, 2020 12:00:45 PM
Aquestive Therapeutics price target lowered to $7 from $8 at RBC Capital »
Aquestive Therapeutics price target lowered to $13 from $18 at BMO Capital 07:00 AQST BMO Capital analyst Gary Nachman lowered the firm's price target on Aquestive Therapeutics to $13 from $18 but keeps an Outperform rating on the shares. The analyst notes that the CRL for the company's key product Libervant announced by the FDA on Friday is "disappointing, but should be very fixable" in the near term. Nachman adds that Aquestive intends to resubmit the study by the end of the year and expects a PDUFA date for the drug in the first half of 2021.
Read more at:
https://thefly.com/n.php?id=3166457
Aquestive Therapeutics price target lowered to $17 from $23 at JMP
Aquestive Therapeutics price target lowered to $17 from $23 at JMP Securities 06:07 AQST JMP Securities analyst Jason Butler lowered the firm's price target on Aquestive Therapeutics to $17 from $23 but keeps an Outperform rating on the shares. The analyst notes that the company's announcement of an FDA CRL for Libervant announced on Friday is disappointing, but he believes that the path to approval remains "timely and low risk". Butler adds that his probability of approval for the drug remains at 85%, though his model pushes back assumptions for its launch and first sales by one year to 2021.
Read more at:
https://thefly.com/n.php?id=3166393Securities »
https://thefly.com/news.php?symbol=AQST
Recent AQST News
- Form 8-K - Current report • Edgar (US Regulatory) • 09/09/2024 12:56:17 PM
- Aquestive Therapeutics to Hold Virtual Investor Day to Provide Pipeline Updates on September 27th • GlobeNewswire Inc. • 09/09/2024 12:15:00 PM
- Aquestive Therapeutics to Participate in Two Upcoming Investor Conferences • GlobeNewswire Inc. • 08/22/2024 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2024 12:08:37 PM
- Aquestive Therapeutics Comments on Recent FDA Approval of Non-Injection-Based Epinephrine Product for the Treatment of Anaphylaxis and Reiterates Expected Timing for NDA Filing of Anaphylm™ • GlobeNewswire Inc. • 08/14/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/12/2024 06:45:02 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 08:26:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/06/2024 08:24:46 PM
- Aquestive Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 08/06/2024 08:22:19 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/25/2024 12:16:24 PM
- Aquestive Therapeutics Reports Positive Topline Data for Anaphylm™ (epinephrine) Sublingual Film from Self-Administration Study • GlobeNewswire Inc. • 07/25/2024 12:00:00 PM
- Aquestive Therapeutics to Report Second Quarter 2024 Financial Results and Recent Business Highlights on August 6 and Host Conference Call on August 7 at 8:00 a.m. ET • GlobeNewswire Inc. • 07/23/2024 12:00:00 PM
- Aquestive Therapeutics to Participate in Leerink Partners Therapeutics Forum: I&I and Metabolism • GlobeNewswire Inc. • 06/27/2024 12:00:00 PM
- Aquestive Therapeutics Reports Positive Topline Data from Temperature / pH Study of Anaphylm™ (epinephrine) Sublingual Film • GlobeNewswire Inc. • 06/25/2024 12:00:00 PM
- Aquestive Therapeutics to Join the Russell 3000® and Russell 2000® Indexes Effective June 28, 2024 • GlobeNewswire Inc. • 06/18/2024 12:00:00 PM
- Form 3/A - Initial statement of beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 06/12/2024 09:14:25 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:36:13 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 06/11/2024 04:35:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/07/2024 12:13:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/06/2024 08:05:52 PM
- Aquestive Therapeutics Announces Executive Appointments and Builds Commercial Capabilities • GlobeNewswire Inc. • 06/03/2024 12:00:00 PM
- Aquestive Therapeutics to Present Anaphylm™ (epinephrine) Sublingual Film Pharmacokinetic and Pharmacodynamic Data At 2024 Eastern Allergy Conference • GlobeNewswire Inc. • 05/28/2024 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:32 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 05:40:07 PM
- Aquestive Therapeutics to Participate in The Citizens JMP Life Sciences Conference • GlobeNewswire Inc. • 05/09/2024 12:00:00 PM
FEATURED Cannabix Technologies and Omega Laboratories Inc. Advance Marijuana Breathalyzer Technology - Dr. Bruce Goldberger to Present at Society of Forensic Toxicologists Conference • Sep 24, 2024 8:50 AM
FEATURED Integrated Ventures, Inc Announces Strategic Partnership For GLP-1 (Semaglutide) Procurement Through MedWell USA, LLC. • Sep 24, 2024 8:45 AM
Avant Technologies Accelerates Creation of AI-Powered Platform to Revolutionize Patient Care • AVAI • Sep 24, 2024 8:00 AM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM